Literature DB >> 17454947

Long-term follow-up of conservatively managed incidental carcinoma of the prostate: a multivariate analysis of prognostic factors.

David Robinson1, Gunnar Aus, Julia Bak, Tomasz Gorecki, Anders Herder, Johan Rosell, Eberhard Varenhorst.   

Abstract

OBJECTIVE: To evaluate the disease-specific mortality of conservatively managed incidental carcinoma of the prostate (T1a and T1b) in relation to prognostic factors.
MATERIAL AND METHODS: Since 1987 all patients with prostate cancer have been recorded and followed in the population-based Prostate Cancer Register of the South-East Healthcare Region in Sweden, which is covered by four departments of pathology. At two of these departments, tissue was obtained from 197 consecutive, previously untreated patients (aged <80 years) with incidental carcinoma who underwent transurethral resection of the prostate between 1987 and 1991. The amount of tumour, Gleason score and levels of Ki-67, p53, chromogranin A and serotonin were determined. Univariate analysis and multiple Cox regression hazard analysis were used for analysis.
RESULTS: During follow-up (mean 7.8 years; maximum 17.5 years), 158 patients (80%) had died, 33 of them of prostate cancer, corresponding to 17% of the entire cohort. Of 86 patients with Gleason score < or =5, three died of prostate cancer. Independent predictors of disease-specific mortality in multivariate analysis were category T1b prostate cancer, Gleason score >5 and high immunoreactivity of Ki-67.
CONCLUSIONS: Elderly men with category T1a and/or Gleason score 4-5 prostate cancer have a favourable prognosis with conservative management. Immunohistochemical staining with Ki-67 may be of help in situations where further prognostic information is required.

Entities:  

Mesh:

Year:  2007        PMID: 17454947     DOI: 10.1080/00365590600991268

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  9 in total

1.  Cause of death in older men after the diagnosis of prostate cancer.

Authors:  Melanie Ketchandji; Yong-Fang Kuo; Vahakn B Shahinian; James S Goodwin
Journal:  J Am Geriatr Soc       Date:  2008-11-18       Impact factor: 5.562

2.  Medical hospitalizations in prostate cancer survivors.

Authors:  Jerome Gnanaraj; Shobana Balakrishnan; Zarish Umar; Emmanuel S Antonarakis; Christian P Pavlovich; Scott M Wright; Waseem Khaliq
Journal:  Med Oncol       Date:  2016-06-20       Impact factor: 3.064

3.  Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies.

Authors:  Mattia Luca Piccinelli; Stefano Luzzago; Giulia Marvaso; Ekaterina Laukhtina; Noriyoshi Miura; Victor M Schuettfort; Keiichiro Mori; Abdulmajeed Aydh; Matteo Ferro; Francesco A Mistretta; Nicola Fusco; Giuseppe Petralia; Barbara A Jereczek-Fossa; Shahrokh F Shariat; Pierre I Karakiewicz; Ottavio de Cobelli; Gennaro Musi
Journal:  World J Urol       Date:  2021-10-23       Impact factor: 4.226

4.  Incidental prostate cancer after holmium laser enucleation of the prostate: incidence and predictive factors for clinical progression.

Authors:  Clément Klein; Thibault Marquette; Grégoire Capon; Mokrane Yacoub; Eric Alezra; Jean-Christophe Bernhard; Franck Bladou; Grégoire Robert
Journal:  Int J Clin Oncol       Date:  2022-03-25       Impact factor: 3.402

5.  Preoperative clinical factors for diagnosis of incidental prostate cancer in the era of tissue-ablative surgery for benign prostatic hyperplasia: a korean multi-center review.

Authors:  Changhee Yoo; Cheol Young Oh; Se Joong Kim; Sun Il Kim; Young Sig Kim; Jong Yeon Park; Do Hwan Seong; Yun Seob Song; Won Jae Yang; Hyun Chul Chung; In Rae Cho; Sung Yong Cho; Sang Hyeon Cheon; Sungjoon Hong; Jin Seon Cho
Journal:  Korean J Urol       Date:  2012-06-19

6.  What Is the Clinical Significance of FDG Unexpected Uptake in the Prostate in Patients Undergoing PET/CT for Other Malignancies?

Authors:  Priya Bhosale; Aparna Balachandran; Raghu Vikram; Chitra Viswanathan; Homer Macapinlac; Eric Rohren; Ramanujan Prativadi
Journal:  Int J Mol Imaging       Date:  2013-12-28

7.  Preoperative parameters to predict incidental (T1a and T1b) prostate cancer.

Authors:  Hirofumi Sakamoto; Kazuhiro Matsumoto; Nozomi Hayakawa; Takahiro Maeda; Atsuko Sato; Akiharu Ninomiya; Kiyoshi Mukai; So Nakamura
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

8.  Incidence and mortality of incidental prostate cancer: a Swedish register-based study.

Authors:  O Andrèn; H Garmo; L Mucci; S-O Andersson; J-E Johansson; K Fall
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

9.  Should all specimens taken during surgical treatment of patients with benign prostatic hyperplasia be assessed by a pathologist?

Authors:  Michał Andrzej Skrzypczyk; Jakub Dobruch; Lukasz Nyk; Przemysław Szostek; Stanisław Szempliński; Andrzej Borówka
Journal:  Cent European J Urol       Date:  2014-08-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.